We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

71 hedge funds and large institutions have $158M invested in Arbutus Biopharma in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

116% more call options, than puts

Call options by funds: $2.01M | Put options by funds: $933K

72% more capital invested

Capital invested by funds: $91.9M → $158M (+$66.3M)

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

42% more funds holding

Funds holding: 50 → 71 (+21)

6.94% more ownership

Funds ownership: 33.37% → 40.32% (+6.9%)

Holders
71
Holders Change
+21
Holders Change %
+42%
% of All Funds
1.63%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
29
Increased
18
Reduced
11
Closed
8
Calls
$2.01M
Puts
$933K
Net Calls
+$1.08M
Net Calls Change
+$712K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$10.1M
2
FCMI
Foresite Capital Management IV
California
+$6.94M
3
State Street
State Street
Massachusetts
+$2.89M
4
Northern Trust
Northern Trust
Illinois
+$1.76M
5
Goldman Sachs
Goldman Sachs
New York
+$1.47M

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$2.68M
2
AC
Ascend Capital
California
-$1.45M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.43M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.04M
5
KPF
K2 Principal Fund
Ontario, Canada
-$777K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$531K +$433K +72,714 New
TA
27
Teachers Advisors
New York
$493K +$402K +67,517 New
PNC Financial Services Group
28
PNC Financial Services Group
Pennsylvania
$493K +$402K +67,605 New
PP
29
PDT Partners
New York
$489K -$32.9K -5,535 -8%
Charles Schwab
30
Charles Schwab
California
$482K +$392K +65,900 New
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$394K +$322K +54,037 New
BFM
32
Boothbay Fund Management
New York
$350K +$286K +48,000 New
Wells Fargo
33
Wells Fargo
California
$339K +$258K +43,325 +1,444%
Mackenzie Financial
34
Mackenzie Financial
Ontario, Canada
$291K – – –
UBS Group
35
UBS Group
Switzerland
$276K -$25K -4,203 -10%
DekaBank Deutsche Girozentrale
36
DekaBank Deutsche Girozentrale
Germany
$254K – – –
AG
37
Algert Global
California
$254K +$207K +34,816 New
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$243K +$199K +33,356 New
SAM
39
Silphium Asset Management
United Kingdom
$242K +$198K +33,195 New
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$218K +$178K +29,896 New
ProShare Advisors
41
ProShare Advisors
Maryland
$203K +$14.2K +2,382 +9%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$179K +$146K +24,500 New
AAMU
43
Amundi Asset Management US
Massachusetts
$171K +$139K +23,400 New
AIG
44
American International Group
New York
$168K +$137K +23,002 New
KPF
45
K2 Principal Fund
Ontario, Canada
$150K -$777K -130,487 -86%
SC
46
Scotia Capital
Ontario, Canada
$145K – – –
AQR Capital Management
47
AQR Capital Management
Connecticut
$140K +$114K +19,222 New
SAM
48
Seelaus Asset Management
New Jersey
$104K – – –
VOYA Investment Management
49
VOYA Investment Management
Georgia
$98K +$79.8K +13,404 New
CS
50
Credit Suisse
Switzerland
$84K +$68.1K +11,436 New
1
2
3

ABUS Hedge Fund Activity: Q2 2018 in Review

71 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2018, worth a combined $158M — up 72% from $91.9M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ABUS positions and 8 closed out — a net gain of 21 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was Axa, exiting entirely with an estimated $2.68M sold.

  • 71 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2018, up from 50 in Q1 2018.
  • Funds reported $158M of Arbutus Biopharma stock for Q2 2018, up 72% quarter-over-quarter.
  • 29 funds opened new Arbutus Biopharma positions in Q2 2018 and 8 closed out, a net change of +21 holders.
  • The largest Arbutus Biopharma buyer in Q2 2018 was BlackRock, an estimated $10.1M added.
  • The largest Arbutus Biopharma seller in Q2 2018 was Axa, an estimated $2.68M sold.

Based on aggregated 13F filings for Q2 2018.